research paper on polio virus

Loading metrics

Open Access

Peer-reviewed

Research Article

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative

Affiliation Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom

Current Address: Janssen Infectious Diseases and Vaccines, Crucell Holland B.V., Leiden, The Netherlands

* E-mail: [email protected]

• Glynis Dunn, 
• Dimitra Klapsa, 
• Thomas Wilton, 
• Lindsay Stone, 
• Philip D. Minor, 
• Javier Martin

• Published: August 27, 2015
• https://doi.org/10.1371/journal.ppat.1005114
• Reader Comments

There are currently huge efforts by the World Health Organization and partners to complete global polio eradication. With the significant decline in poliomyelitis cases due to wild poliovirus in recent years, rare cases related to the use of live-attenuated oral polio vaccine assume greater importance. Poliovirus strains in the oral vaccine are known to quickly revert to neurovirulent phenotype following replication in humans after immunisation. These strains can transmit from person to person leading to poliomyelitis outbreaks and can replicate for long periods of time in immunodeficient individuals leading to paralysis or chronic infection, with currently no effective treatment to stop excretion from these patients. Here, we describe an individual who has been excreting type 2 vaccine-derived poliovirus for twenty eight years as estimated by the molecular clock established with VP1 capsid gene nucleotide sequences of serial isolates. This represents by far the longest period of excretion described from such a patient who is the only identified individual known to be excreting highly evolved vaccine-derived poliovirus at present. Using a range of in vivo and in vitro assays we show that the viruses are very virulent, antigenically drifted and excreted at high titre suggesting that such chronic excreters pose an obvious risk to the eradication programme. Our results in virus neutralization assays with human sera and immunisation-challenge experiments using transgenic mice expressing the human poliovirus receptor indicate that while maintaining high immunisation coverage will likely confer protection against paralytic disease caused by these viruses, significant changes in immunisation strategies might be required to effectively stop their occurrence and potential widespread transmission. Eventually, new stable live-attenuated polio vaccines with no risk of reversion might be required to respond to any poliovirus isolation in the post-eradication era.

Author Summary

The global polio eradication initiative is the most ambitious and complex public health programme directed at a single disease in history with a projected cost of $16.5 billion. Of the three serotypes types 2 and 3 appear to have been eradicated in the wild and type 1 is mostly confined to a region of Pakistan and Afghanistan. There is a real probability of total eradication in the near future. The main vaccine used is a live attenuated virus, and our paper concerns one of the most intractable significant implications that this has for the polio endgame. We describe virological studies of a patient deficient in humoral immunity who has been excreting type 2 vaccine-derived poliovirus for 28 years. Our results show that the viruses are excreted at high titres, extremely virulent and antigenically drifted and raise questions about how the population may best be protected from them, particularly in the light of possible changes in vaccine production which are being encouraged to increase capability and reduce costs. The study has implications for the ecology of poliovirus in the human gut and highlights the risks that such vaccine-derived isolates pose for polio re-emergence in the post-eradication era.

Citation: Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J (2015) Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. PLoS Pathog 11(8): e1005114. https://doi.org/10.1371/journal.ppat.1005114

Editor: Vincent Racaniello, Columbia University, UNITED STATES

Received: June 7, 2015; Accepted: July 28, 2015; Published: August 27, 2015

Copyright: © 2015 Dunn et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Data Availability: All relevant data are within the paper. Nucleotide sequences of iVDPV and wild poliovirus isolates described in this paper have been deposited in the DDBJ/EMBL/GenBank and have been assigned accession numbers KR817050-KR817066.

Funding: The study was funded by NIBSC core funds and partly by the Regulatory Science Research Unit of the UK Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Despite difficulties in interrupting wild poliovirus transmission in the last few remaining endemic countries and recent drawbacks due to international spread of poliovirus in central Asia, central Africa and the Middle East [ 1 ], the global polio eradication appears to be within reach. Four of the six WHO regions have been certified polio-free and a country such as India, where massive poliomyelitis outbreaks were very common, interrupted circulation of endemic wild poliovirus in 2010. There has been no case of poliomyelitis caused by circulating wild type 2 poliovirus since 1999, no case of type 3 since November 2012 and the last case of type 1 in Africa was in August 2014, leaving some areas of Pakistan and Afghanistan as the main remaining reservoirs [ 2 ]. All type 2 poliomyelitis cases since 1999, except an isolated incident of 10 cases linked to a wild laboratory reference strain in India [ 3 ], are due to vaccine-related poliovirus strains in either recipients, their immediate contacts or after the vaccine virus has regained the ability to transmit and circulate freely. Vaccine-associated paralytic poliomyelitis occurs in a very small proportion of vaccinees [ 4 ] and can be prevented by using inactivated rather than live vaccine. Vaccine-derived poliovirus (VDPV) strains, defined as those with more than 1% (0.6% for serotype 2 poliovirus) sequence drift in the capsid VP1 gene with respect to the corresponding Sabin strain, can be generated and transmitted from person to person in populations with low immunity and have been associated with a number of poliomyelitis outbreaks around the world [ 5 – 9 ]. These circulating VDPVs (cVDPVs) behave very similarly to wild polioviruses and should therefore be eliminated by the same immunisation methods. In addition, some hypogammaglobulinaemic patients are known to excrete poliovirus for prolonged periods of time [ 10 – 12 ] but there is currently no effective strategy to deal with this problem. Although there has been some evidence of local virus transmission from these patients to unvaccinated children [ 13 ], VDPV strains from immunodeficient individuals (iVDPVs) have not yet been implicated in outbreaks in the same way that cVDPVs have [ 14 ]. The World Health Organization (WHO) and partners have prepared endgame plans for the global polio eradication initiative (GPEI) which include the elimination of the serotype 2 component from the Sabin live-attenuated oral poliovaccine (OPV) and the implementation of global use of inactivated poliovaccine (IPV) [ 15 ]. This represents a major change after more than 50 years of trivalent OPV use for routine immunisation although monovalent and bivalent vaccines are commonly used for campaigns on national immunisation days.

The risks posed by iVDPV strains and the prevalence of such cases globally are unknown so their relevance in the context of the GPEI endgame is not easy to assess. In order to better understand the growth and properties of iVDPV strains and their potential for transmission, we have characterised iVDPV isolates from an immunodeficient individual obtained during a period of more than 20 years. Although examples of long-term poliovirus excretion have been described before by us and others (reviewed in [ 14 ]), they have mostly included a small number of samples from paralytic cases as otherwise asymptomatic long-term excreters remain undetected. In previous cases patients died, stopped shedding virus or were lost to follow up relatively soon after the first virus isolation. Important gaps in the scientific knowledge of long-term poliovirus excretion by these individuals remained such as determining changes in excretion titres, antigenic structure and neurovirulence of poliovirus following many years of evolution in a single individual as well as estimating the efficacy of current vaccines at preventing paralysis and transmission induced by these viruses. Our paper provides relevant findings in these areas that indicate that VDPV isolates form these patients represent a real risk of polio re-emergence in the post-eradication era, particularly considering there is currently no effective strategy to treat these patients.

Results and Discussion

The first stool samples from this individual were tested between March and November 1995. At that time, type 2 VDPV isolates differing from the parental Sabin 2 OPV strain at between 9.9% and 11.3% of VP1 nucleotides were identified. A total of 185 subsequent samples have been obtained so far in the following years, all positive for iVDPV2 strains with virus titres shed in the stools typically around or above 4 log 10 infectious particles per gram, comparable to virus titres shed by healthy vaccinees and paralytic cases infected with vaccine or wild poliovirus [ 16 ]. The latest isolate available was from 4 th March 2015 showing a 17.7% VP1 sequence drift from Sabin 2 poliovirus. Phylogenetic analyses in the capsid region confirmed that the iVDPV strains were genetically related, sequentially evolved from Sabin 2 and distinct from other type 2 VDPVs and wild polioviruses ( Fig 1 ).

• PPT PowerPoint slide
• PNG larger image
• TIFF original image

Neighbour-joining tree representing phylogenetic relationships through the entire capsid coding sequence (2637 nt) between iVDPV isolates from the case study (shown as a number that corresponds to the date of isolation in the format ddmmyy ), Sabin 2 vaccine strain and other type 2 VDPV and wild polioviruses. EMBL Data Library accession numbers for published capsid sequences are shown in the tree. Numbers at nodes indicate the percentage of 1000 bootstrap pseudoreplicates supporting the cluster. The sequence of PV1-Mahoney reference strain was introduced as an outgroup for the correct rooting of the tree. Isolates from the patient are labelled with blue circles on the tree, other iVDPV isolates are indicated in yellow, cVDPVs in red, VDPVs found in sewage samples in green and wild polioviruses in purple.

https://doi.org/10.1371/journal.ppat.1005114.g001

A Bayesian Monte Carlo Markov Chain (MCMC) phylogenetic analysis determined a mean evolutionary rate of 1.51×10 −2 total substitutions/site/year [95% High Probability Distribution (HPD 95 ) range = 1.26–1.77×10 −2 ] in the VP1 gene, similar to previous estimates for poliovirus VP1 [ 17 ]. The date of the initiating OPV dose was estimated to be 11 th March 1986 [HPD 95 = 6 th July 1983-11 th January 1989], relatively close to 4 th August 1986, the date of the patient’s last known OPV vaccination. It is therefore most likely that this individual has been excreting poliovirus for around 28 years. There was no apparent effect on the virus evolution rate suggesting bottleneck effects due to the anti-viral treatments that failed to interrupt virus excretion from this patient [ 18 ]. However, a much more detailed analysis of virus population dynamics should be conducted to determine any possible effect due to the different anti-viral interventions.

All iVDPV isolates showed reversion at the two known attenuation mutations of Sabin 2 vaccine strain: nucleotide 481 (from A to G) in the 5’ non-coding region (5’NCR) and capsid amino acid VP1-143 (from Isoleucine to Threonine) and were highly neurovirulent in transgenic mice expressing the human poliovirus receptor. The 50% paralytic dose (PD50) values were comparable to those determined for cVDPV and wild polioviruses while the Sabin 2 vaccine strain did not paralyse any animals at the highest dose that could be given ( Fig 2 ).

The graphic represents 50% Paralytic Doses (PD 50 ) values (with 95% Confidence Intervals) for selected poliovirus strains determined in Tg21-bx mice using the Probit method. Isolates from the patient are shown underlined.

https://doi.org/10.1371/journal.ppat.1005114.g002

Amino acid differences with respect to the Sabin 2 parental strain in the complete coding sequence of selected iVDPV isolates were determined ( S1 Table ). All iVDPV strains contained identical changes from Sabin 2 at 52 amino acid positions. Forty mutations were present in at least two iVDPV isolates and 24 amino acid changes were unique. The proportion of nucleotide mutations leading to amino acid changes was high for all iVDPV strains. This contrasts with the low proportion of non-synonymous changes from Sabin 2 identified in cVDPV strains and wild isolates as found here and elsewhere, particularly in capsid sequences. It is not clear whether any of the numerous additional mutations incorporated in the iVDPV isolates have any effect on neurovirulence but they do not seem to have an overall mitigation impact for any of the isolates tested as it has been reported for one highly drifted type 2 VDPV isolate found in a sewage sample in Israel [ 19 ]. Many of the sequence changes between the iVDPV strains and the Sabin 2 virus resulted in amino acid differences in known antigenic sites [ 20 ] ( Table 1 ).

https://doi.org/10.1371/journal.ppat.1005114.t001

As a consequence, the iVDPV strains did not react at all with monoclonal antibodies against most of the known neutralising antibody sites ( Fig 3 ). It was of interest that all isolates tested did react with antibodies specific for antigenic site 3b (1102 and 1103). In contrast, the wild polioviruses strains analysed, which span almost four decades in time and which were isolated in geographically distant locations, exhibited an antigenic structure much closer to that of Sabin 2 virus, reacting with at least one monoclonal antibody specific for each antigenic site ( Fig 3 ). A cVDPV strain from Madagascar [ 21 ] also reacted with most monoclonal antibodies.

Radial diagrams representing the reactivity of poliovirus strains with Sabin 2-specific monoclonal antibodies. The results are shown as OD values at 492nm obtained in ELISA assays and expressed as normalised values relative to those obtained with antibody 1102 which reacted with all poliovirus strains. These values denote the average of two duplicate assays. Monoclonal antibodies used in the assay in the order 1 to 14 shown in the graph (from the top and clockwise), with antigenic site specificity shown in brackets, were: 969 (site 1), 435 (1), 433 (1), 434 (1), 436 (1), 1231 (2a), 1247 (2a), 1269 (2a), 1037 (2b), 1050 (3a), 1102 (3b), 1103 (3b), 1121 (3b) and 1051 (3b). Sabin 2 vaccine virus, iVDPV isolates from the patient (160198, 190100, 080503, 071108 and 171012), cVDPV strain MAD029 and wild strains (EGY42, EGY52, VEN59, MOR78 and KUW80) were used in the assays.

https://doi.org/10.1371/journal.ppat.1005114.g003

There was no evidence of sequences derived from Sabin 1 or Sabin 3 poliovirus vaccine strains nor sequences derived from other polio or non-polio human enterovirus isolates in any iVDPV genome examined. There was therefore no indication of recombination with other enteroviruses, although recombination within the iVDPV population is quite possible [ 22 , 23 ]. In contrast, virtually all cVDPV and wild type polio strains are recombinants with other group C enteroviruses and include sequences from the 5’NCR and/or the non-structural coding region [ 21 , 24 ].

Despite the extensive antigenic changes found in iVDPV strains ( Fig 4 ), human sera readily neutralised iVDPV isolate 160198, the most antigenically divergent strain ( Fig 5 ). This isolate was the only one obtained by plaque purification so it might represent a minor variant with slightly different antigenic makeup.

Molecular surface diagram of the three-dimensional structure of type 2 wild poliovirus strain Lansing viewed from the outside of the virion [ 25 ]. A pentameric unit is represented. The virus particle consists of 60 protomers. Each protomer contains a single copy of VP1, VP2, VP3, and VP4 arranged in icosahedral symmetry. The location of mutations found in known antigenic sites of iVDPV isolate 160198 with respect to Sabin 2 vaccine strain are shown in red, other amino acid changes from Sabin 2 are displayed in cyan. The image was generated using PyMOL Molecular Graphics System, Version 1.7.0.3 software (Schrödinger, LLC).

https://doi.org/10.1371/journal.ppat.1005114.g004

The graphs represent comparison of neutralization titres in 40 sera from UK adults against iVDPV isolate 160198 versus MEF-1 (A) or versus Sabin 2 (B) vaccine strains in cell culture assays. The values are expressed as reciprocals (Log2) of the highest dilution of serum that protected 50% of the cell cultures determined by the Karber formula.

https://doi.org/10.1371/journal.ppat.1005114.g005

The log2 geometric mean titre (GMT) of antibodies neutralizing iVDPV virus 160198 in 40 serum samples from UK adults was 9.96±2.78 comparable to that against MEF-1 (log2 GMT = 10.20±2.40), the wild poliovirus strain used for IPV production, and Sabin 2 (log2 GMT = 10.49±2.02), used for OPV production. These differences were not statistically significant (P = 0.95 for iVDPV vs MEF-1 and P = 0.36 for iVDPV vs Sabin2, for paired results using the Wilcoxon signed-rank test). The results suggest that antibodies to antigenic site 3b in human sera, partially conserved in iVDPV strains, may be sufficient to neutralise the virus. Alternatively, other conserved antigenic epitopes not detected by our murine antibody panel but present in the iVDPV strains, could have contributed to the high neutralization levels shown in human sera. These results are reassuring in that they indicate that vaccinated humans are well protected against infection with these highly drifted iVDPV strains. However, the sera tested here correspond to a selected group of UK healthy adults between 28–65 years of age who had been vaccinated with a full course of four OPV doses plus at least one dose of IPV. The UK switched from OPV to IPV for polio immunisation in 2004 so it would be helpful to test sera from cohorts that have only received IPV immunisation. Israel, which also switched from OPV to IPV at a similar date (2005), has recently detected the widespread circulation of type 1 wild poliovirus through environmental surveillance. There were no paralytic cases but, like the iVDPVs reported here, isolates from Israel showed antigenic differences from the corresponding vaccine strain which may have contributed to their ability to circulate in the context of IPV immunity [ 26 ].

We used a transgenic mouse model [ 27 ] to test the ability of different IPV products to protect against paralysis caused by iVDPV strains. Both conventional IPV (cIPV) based on wild poliovirus strains and Sabin IPV (sIPV) based on OPV strains were used ( Fig 6 ).

Survival curves showing animals protected against paralysis caused by MEF-1 (A) or iVDPV strain 171012 (B) following immunisation with conventional (cIPV) products are shown with opened symbols and continuous lines; results for Sabin IPV (sIPV) products are shown as dashed lines and closed symbols; and survival data for mice injected with diluent (control) are shown as dotted lines and inverted triangles. All three cIPV products showed 100% protection against challenge with both viruses with the exception of cIPV-C that protected 7 out of the 8 animals used in the test. sIPV-A vaccine also protected all immunised animals against challenge with the MEF-1 strain.

https://doi.org/10.1371/journal.ppat.1005114.g006

All unimmunised control mice were severely paralysed by 5 days (MEF-1 virus) or 8 days (iVDPV strain) post-challenge. All three cIPV products protected against both challenge strains with only one animal developing paralysis. In contrast, sIPV products were less effective at protecting mice and showed variable responses between them. For all vaccines, the in vitro neutralizing antibody titers in sera from immunized mice were at least 7-fold lower against the iVDPV strain than they were against MEF-1 virus ( Table 2 ).

https://doi.org/10.1371/journal.ppat.1005114.t002

Our results highlight the need for improving the standardisation of sIPV products in terms of measuring vaccine potency and defining the protective human dose. The lower immunogenicity shown by type 2 sIPVs has been reported before [ 28 , 29 ].

In conclusion, we describe a patient who has been excreting highly virulent and antigenically modified type 2 poliovirus at high titres for a period estimated to be twenty eight years so far. This is by far the longest reported poliovirus excretion and represents the most comprehensive collection of iVDPV sequential isolates available. Provided antibody titres and immunisation coverage are maintained it is likely that the population will be protected against paralytic disease, but it is also possible that this virus could circulate in populations only using IPV as described in Israel for wild poliovirus [ 26 ], thus representing a possible source of polio re-emergence, particularly as these iVDPV strains are antigenically atypical and drifted from both Sabin 2 and MEF-1 vaccine strains. This is particularly relevant at present as there are imminent plans to remove type 2 poliovirus from OPV [ 15 ]. Moreover the use of IPV based on the Sabin strains is being encouraged by WHO for reasons of environmental safety and the data presented here suggest that it is less effective.

Of the total of 73 iVDPV cases that have been described between 1962 and 2014 [ 14 ], only seven of them involved infections lasting more than five years. The case described here represents the only individual of those seven known to be excreting at present. However, several highly drifted VDPV strains have recently been isolated from sewage samples in Slovakia, Finland, Estonia and Israel [ 30 ]. They included examples of all three poliovirus serotypes, although type 2 VDPVs were the most prevalent among them. These VDPV isolates showed molecular properties typical of iVDPVs described above indicating that an unknown number of these chronic excreters exist elsewhere. Interestingly, highly evolved type 1 and 2 VDPVs, which have been repeatedly isolated in Israel’s sewage in the last few years, do not appear to have spread widely as type 1 wild poliovirus did. Enhanced surveillance including sewage sampling and stool surveys should continue for as long as possible to search for the presence of iVDPV strains. The availability of efficient anti-viral treatments to interrupt virus replication in these individuals, actively being pursued at present [ 31 ], would also be vital as previous attempts have failed [ 18 ]. These measures are needed to be able to identify and manage the possible risks of iVDPV strains spreading and causing disease in patients and the general population, particularly in the light of changes in vaccination strategies as part of the polio eradication endgame and the absence of an established outbreak response strategy. Just as the use of new monovalent and bivalent vaccines proved essential to the elimination of wild poliovirus [ 32 , 33 ], novel vaccines unable to cause poliomyelitis would be useful at this stage of polio eradication. New polio vaccines such as those based on non-infectious virus-like particles or even new genetically designed stable live-attenuated versions [ 34 – 37 ] with no associated risk of producing VDPVs, might be required to resolve the “OPV paradox” that derives from using OPV to respond to outbreaks and generating new VDPVs as a consequence.

Materials and Methods

Case report.

The patient is a white male from the UK. He received a full course of childhood immunisations, including OVP at 5, 7, and 12 months, with a booster at about 7 years of age. He was later diagnosed with common variable immunodeficiency (CVID) and started on intramuscular immunoglobulin therapy, which was changed to intravenous immunoglobulin after that [ 18 ].

Poliovirus isolation from stool samples

Poliovirus was isolated from 10% stool suspensions using HEp-2c cells. Type 2 iVDPV strains 6735 and 04–44149261, isolated from two other immunodeficient patients in the UK, and type 2 wild poliovirus strains EGY42 (MEF-1 strain used for IPV production), EGY52, VEN59, MOR78 and KUW80 isolated from paralytic cases in 1942, 1952, 1959, 1978 and 1980, respectively, were also characterised in this study.

Nucleotide sequencing of poliovirus genomes

Purified viral RT-PCR DNA products were sequenced by the Sanger method on an ABI Prism DNA 377 Sequencer as specified by the manufacturer. Primers VDPV-F2 (5’-AGG GTT GTT GTC CCG YTG TCC AC-3’) and VDPV-R1 (5’-TAC ACA GCT GGY TAC AAA ATT TGC A-3’) were used to amplify and sequence VP1 gene sequences.

Full genome.

Nearly full genomes of selected poliovirus isolates were sequenced using a deep sequencing method described before [ 38 ]. Sequence-independent amplification was performed to generate dsDNA templates using primers RA10-N8 (5´- GAC CAT CTA GCG ACC TCC CAN NNN NNN N -3 and RA10 (5´- GAC CAT CTA GCG ACC TCC CA -3´). Sequencing libraries were prepared using Nextera XT reagents and sequenced on a MiSeq using a 2 x 251 paired-end v2 Flow Cell and manufacturer’s protocols (Illumina). Raw sequence data were imported into Geneious R7 (Biomatters) and paired end reads combined. Data were filtered and aligned using a custom workflow with the following parameters: shotgun primer RA10 and Nextera adaptor/index sequences were trimmed from 5 and 3´ ends with a minimum 5 bp overlap; reads were trimmed to have an average error rate < 1%, no bases with a quality of < Q30 and no ambiguities. Reads were then mapped to the sequence of the Sabin 2 poliovirus reference (GenBank AY184220) and a consensus sequence obtained for each poliovirus strain. Nucleotide sequences of iVDPV and wild poliovirus isolates described in this paper have been deposited in the DDBJ/EMBL/GenBank and have been assigned accession numbers KR817050-KR817066.

Phylogenetic analysis.

Poliovirus sequences were compared to those of other polioviruses in the DDBJ/EMBL/GenBank database. Representative related sequences were included in the phylogenetic analyses. Neighbour-joining phylogenetic analysis was performed with MEGA6 [ 39 ] using the maximum composite likelihood substitution model with gamma distributed substitution rates. In addition, a Bayesian Monte Carlo Markov Chain (MCMC) analysis of VP1 sequences (42 iVDPV isolates from the patient obtained throughout the period of virus excretion), as implemented in BEAST v1.8.1 [ 40 ], was used for the estimation of the rate of evolution and the date of the initiating OPV dose. The general time reversible (GTR) model of substitution with invariant sites was the best-fitting model of evolution as estimated by jMODELTEST [ 41 ]. Two independent chains of 10 million steps each were run under the strict clock model, assuming a constant substitution rate as estimated from the data set. The samples’ collection dates were included as temporal data. Effective sample size values were monitored for consistency using Tracer v1.6.

Neurovirulence in transgenic mice

Tg21-Bx transgenic mice expressing the human poliovirus receptor were inoculated intramuscularly (left hind limb) with 50 μl of 10-fold viral dilutions and daily clinical scores were recorded for 14 days. Eight mice were used for each viral dilution. The Probit method was used to calculate the 50% paralytic dose (PD 50 ) and associated 95% confidence intervals for each poliovirus challenge [ 27 ].

Antigenic characterization

The antigenic properties of poliovirus isolates were studied by analysing their ability to bind Sabin 2-specific monoclonal antibodies in ELISA assays using testing formats described before [ 42 ]. Antibodies corresponding to antigenic sites 1, 2a, 2b and 3b were used in these assays. Solutions containing equivalent concentrations of poliovirus measured as 50% cell culture infectious doses (CCID 50 ) per ml were selected. The results represent the OD values at 492nm and were expressed as normalised values relative to those obtained with antibody 1102 which reacted with all poliovirus strains.

Immunization/Challenge experiments in transgenic mice

Tg21-Bx mice (8 per test group) were immunised twice by intraperitoneal injection with IPV (using the equivalent of 1 human dose/mouse) or minimum essential medium (diluent control) at an interval of 2 weeks. Twenty-one days after the last dose, mice were challenged with the equivalent of 25 times the PD 50 of live poliovirus and daily clinical scores were recorded for 14 days [ 27 ]. Vaccines used in these experiments were kindly donated by various manufacturers and were coded to maintain anonymity. This work was part of the characterisation of these vaccines as reference standards. It is important to note that given the high PD 50 values observed for type 2 poliovirus strains in our transgenic mouse neurovirulence model, mice were challenged with very large amounts of virus (around 10 8 CCID 50 /mouse).

Titration of human and mouse sera for poliovirus neutralising antibodies

Neutralizing antibody titres in serum samples were determined by a standard microneutralization assay in 96-well plates. Two-fold serial dilutions of serum were preincubated with one hundred CCID 50 of virus for 2 hours at 36°C. HEp-2C cells were added to each well, and survival at day 5 post-infection determined by staining with a 0.1% Naphthalene black solution. Antibody titres were expressed as reciprocals (Log2) of the highest dilution of serum that protected 50% of the cell cultures determined by the Karber formula. Virus challenge doses were confirmed by back-titration. The significance of pairwise differences in neutralization titres of human sera against MEF-1, Sabin 2 and iVDPV 160198 strain was determined using the Wilcoxon signed-rank test.

Ethics statement

The adult subject who provided stool samples gave written informed consent. Adults who provided blood samples also provided written informed consent. The work complies with the Caldicott Principles and Recommendations for patient confidentiality set up by the UK National Health Services (NHS). All links to personal details that could be used to identify individuals were removed and data were analysed anonymously when possible. No samples from children were involved in the study. The study was approved by NIBSC’s Ethics and Human Materials Advisory Committees. NIBSC’s Animal Welfare and Ethical Review Body approved the application for Procedure Project Licence Number 80/2478 which was approved by the UK Government Home Office and under which animal care and protocols shown in this paper were conducted. All animal care and protocols used at NIBSC adhere to UK regulations (Animals, scientific procedures, Act 1986 that regulates the use of animals for research in the UK) and to European Regulations (Directive 2010/63/Eu of the European Parliament on the protection of animals used for scientific purposes). The experiments in mice shown here were carried out following protocols 4 and 5 within Home Office Procedure Project Licence Number 80/2478 referred above.

Supporting Information

S1 table. amino acid changes in ivdpv isolates..

Mutations in amino acid sites between iVDPV isolates and Sabin 2 vaccine virus are shown.

https://doi.org/10.1371/journal.ppat.1005114.s001

Acknowledgments

We thank Lisa Johnson, Edward Mee, Thomas Dougall, Gillian Cooper and Laura Crawt for assistance and advice.

Author Contributions

Conceived and designed the experiments: JM. Performed the experiments: GD DK TW LS JM. Analyzed the data: JM. Contributed reagents/materials/analysis tools: GD DK TW LS JM. Wrote the paper: JM PDM.

• 1. World Health Organization (2014) WHO statement on the meeting of the International Health Regulations Emergency Committee concerning the international spread of wild poliovirus. May 5, 2014.
• 2. World Health Organisation (2015) Polio Case Count.
• View Article
• PubMed/NCBI
• Google Scholar

Poliovirus returns to the UK after nearly 40 years: current efforts and future recommendations

Affiliations.

• 1 Oli Health Magazine Organization, Research and Education, Kigali, Rwanda [email protected].
• 2 Clinton Global Initiative University, New York, New York, USA.
• 3 Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
• 4 Oli Health Magazine Organization, Research and Education, Kigali, Rwanda.
• 5 Department of Community Health, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
• 6 Faculty of Medicine, Beirut Arab University Alumnus, Beirut, Lebanon.
• 7 Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
• 8 Faculty of Sciences, Lebanese International University, Beirut, Lebanon.
• 9 Faculty of Basic Medical Sciences, University of Ilorin, Kwara State, Nigeria.
• 10 Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
• 11 School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK.
• 12 Faculty of Medicine, Cardiff University School of Medicine, Cardiff University, Cardiff, UK.
• PMID: 36126982
• PMCID: PMC9613858
• DOI: 10.1136/pmj-2022-142103

On 22 June 2022, the UK Health Security Agency declared a 'rare national incidence' after finding poliovirus in sewage in London for the first time in nearly 40 years. Although no cases of the disease or accompanying paralysis have been documented, the general public's risk is considered minimal. However, public health experts recommend that families are up to date on their polio vaccines to decrease the chance of harm. This article discusses the epidemiology of poliovirus by examining the aetiology of the disease and current mitigation policies implemented to prevent the spread of type 2 vaccine-deceived poliovirus in the UK. Finally, by examining the clinical features of polio, which range from mild gastroenteritis episodes, respiratory sickness, malaise and severe paralysis type, this article offers an advice on particular therapies and tactics to avoid poliovirus outbreaks and other future outbreaks.

Keywords: EPIDEMIOLOGY; Health policy; Public health; VIROLOGY.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Publication types

• Poliomyelitis* / epidemiology
• Poliomyelitis* / prevention & control
• Poliovirus*
• United Kingdom / epidemiology

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• NEWS EXPLAINER
• 22 August 2022

Spate of polio outbreaks worldwide puts scientists on alert

• Heidi Ledford

You can also search for this author in PubMed   Google Scholar

The discovery of poliovirus in New York state, London and Jerusalem this year has taken many by surprise — but public-health researchers fighting to eradicate the disease say it was only a matter of time.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

185,98 € per year

only 3,65 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

Nature 609 , 20-21 (2022)

doi: https://doi.org/10.1038/d41586-022-02233-6

Link-Gelles, R. et al. Morb. Mortal. Wkly Rep . 71 , 1065–1068 (2022).

Article   PubMed   Google Scholar  

Download references

Reprints and permissions

Related Articles

• Public health

Adopt universal standards for study adaptation to boost health, education and social-science research

Correspondence 02 APR 24

Abortion-pill challenge provokes doubt from US Supreme Court

News 26 MAR 24

The future of at-home molecular testing

Outlook 21 MAR 24

Depleting myeloid-biased haematopoietic stem cells rejuvenates aged immunity

Article 27 MAR 24

Bird-flu threat disrupts Antarctic penguin studies

News 15 MAR 24

Fungal diseases are spreading undetected

Outlook 14 MAR 24

Video: Cancer-busting vaccines

Outline 27 MAR 24

Cancer-vaccine trials give reasons for optimism

How does a cancer vaccine work?

Career Opportunities at the Yazhouwan National Laboratory, Hainan, China

We are seeking scientists in various disciplines relevant to agricultural sciences, with a keen interest in candidates specializing in thematic areas.

Sanya, Hainan, China

Yazhouwan National Laboratory

Postdoctoral Associate- Cell Biology

Houston, Texas (US)

Baylor College of Medicine (BCM)

Head of ClinicalTrials.gov

National Institutes of Health (NIH) National Library of Medicine (NLM) National Center for Biotechnology Information (NCBI) Information Engineering...

Washington D.C. (US)

National Library of Medicine, National Center for Biotechnology Information

POSTDOCTORAL FELLOWSHIP IN SYSTEMS BIOLOGY: PRECISION VACCINE PROGRAM (PVP) - BOSTON CHILDREN'

The Data Management and Analysis Core (DMAC) within the Precision Vaccine Program (PVP) at Boston Children’s Hospital and Harvard Medical School (H...

Boston, Massachusetts

Boston Children's Hospital - Department of Pediatrics

2024 Recruitment notice Shenzhen Institute of Synthetic Biology: Shenzhen, China

The wide-ranging expertise drawing from technical, engineering or science professions...

Shenzhen,China

Shenzhen Institute of Synthetic Biology

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Cookies on GOV.UK

We use some essential cookies to make this website work.

We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.

We also use cookies set by other sites to help us deliver content from their services.

You have accepted additional cookies. You can change your cookie settings at any time.

You have rejected additional cookies. You can change your cookie settings at any time.

• Health and social care
• Public health
• Health protection
• Health surveillance and reporting programmes
• Notifiable diseases: causative agents reports for 2024
• UK Health Security Agency

NOIDs causative agents: week 13 (week ending 31 March 2024)

Updated 2 April 2024

Applies to England and Wales

© Crown copyright 2024

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected] .

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/notifiable-diseases-causative-agents-reports-for-2024/noids-causative-agents-week-13-week-ending-31-march-2024

Laboratories in England have a statutory duty to notify the UK Health Security Agency of the identification of the following causative agents:

• Bacillus anthracis
• Bacillus cereus
• Bordetella pertussis
• Borrelia spp
• Brucella spp
• Burkholderia mallei
• Burkholderia pseudomallei
• Campylobacter spp
• Carbapenemase-producing Gram-negative bacteria
• Chikungunya virus
• Chlamydophila psittaci
• Clostridium botulinum
• Clostridium perfringens
• Clostridium tetani
• Corynebacterium diphtheriae
• Corynebacterium ulcerans
• Coxiella burnetii
• Crimean-Congo haemorrhagic fever virus
• Cryptosporidium spp
• Dengue virus
• Ebola virus
• Entamoeba histolytica
• Escherichia coli O 157
• Francisella tularensis
• Giardia lamblia
• Guanarito virus
• Haemophilus influenzae (invasive)
• Hanta virus
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Hepatitis D
• Hepatitis E
• Influenza virus
• Junin virus
• Kyasanur Forest disease virus
• Lassa virus
• Legionella spp
• Leptospira interrogans
• Listeria monocytogenes
• Machupo virus
• Marburg virus
• Measles virus
• Mumps virus
• Mycobacterium tuberculosis complex
• Neisseria meningitidis
• Omsk haemorrhagic fever virus
• Plasmodium falciparum
• Plasmodium Knowlesi
• Plasmodium Malariae
• Plasmodium Ovale
• Plasmodium Vivax
• Polio virus
• Rabies virus
• Rickettsia spp
• Rift Valley fever virus
• Rubella virus
• Sabia virus
• Salmonella spp
• SARS Coronavirus
• Shigella spp
• Streptococcus group A (invasive)
• Streptococcus pneumoniae (invasive)
• Varicella zoster virus
• Variola virus
• Vibrio cholerae
• West Nile virus
• Yellow fever virus
• Yersinia pestis

1. Statutory Notifications of causative agents, grouped by root organism

Totals for the current week compared to the previous five.

2. Carbapenemase-producing Enterobacterales ( CPE )

For all Carbapenemase-producing Gram-negative organisms, the reports are de-duplicated by first mention of organism species and resistance mechanism by person in a rolling 52-week period.

Note: the numbers presented here do not include specimens that have been referred to the  AMRHAI  Reference Unit.

3. Other carbapenemase-producing Gram-negative organisms

Is this page useful.

• Yes this page is useful
• No this page is not useful

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.

To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Ann Med Surg (Lond)
• v.80; 2022 Aug

Poliomyelitis in Pakistan: Challenges to polio eradication and future prospects

Haroon shabbir.

a Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan

Sajeel Saeed

Muhammad farhan.

b Department of Surgery, Rawalpindi Medical University, Rawalpindi, Pakistan

Khawar Abbas

Mohammad ebad ur rehman, jawad basit.

Poliomyelitis is a viral disease that causes acute paralysis, muscle weakness and autonomic dysfunction. It primarily affects children under the age of five. It is mainly transmitted via the feco-oral route, through contaminated water. As of the year 2022, Pakistan remains one of the two countries where polio is still endemic, the other being Afghanistan. Numerous myths and misconceptions regarding the polio vaccine, lack of awareness and proper governance, terrorism and difficult access to remote areas due to poor infrastructure are just some of the reasons why polio remains endemic in Pakistan to this day. Therefore, the government should take measures to ensure the safety and wellbeing of health care workers, as well as spread awareness regarding the importance of polio vaccines, while addressing the myths and misconception regarding said vaccines.

Dear Editor,

Poliomyelitis is an acute paralytic disease that primarily affects children under the age of five. It is caused by a single-stranded positive-sense RNA virus i.e., Polio Virus (PV), which is found in three serotypes (type 1, 2, and 3). Owing to the Global Polio Eradication initiative by the World Health Organization, since 1988, there has been a 99.9% decline in polio cases across the globe [ 1 ]. Around three billion children have been vaccinated by this program over the past 33 years. As of 2022, Pakistan remains one of the two countries where polio is still endemic [ 1 ]. Fig. 1 has shown the number of cases from 2015 till now in Pakistan year-wise [ 2 ].

WPV cases in Pakistan.

Poliovirus is a member of the Picornaviridae family and species Enterovirus C [ 3 ]. Of its three serotypes, types 2 and 3 are considered eradicated as of 2015 [ 4 ]. Poliovirus is the primary causative agent of both acute polio and Post-Polio Syndrome (PPS). Poliomyelitis prognosis is characterized by three distinct phases i.e., acute, recovery, and the residual-paralysis phase. Patients in the acute phase present with pyrexia, paraparesis, muscular weakness, and autonomic dysfunction [ 4 ]. The number of muscle fibers innervated by a single motor neuron i.e., motor unit, increases during the recovery phase. The patient is left with imbalanced muscle power, poor posture, and residual paralysis in the last phase. Of the total cases, around five percent develop paralysis. The remaining infections are non-paralytic. Regarding Post-Polio Syndrome, it is a progressive disorder characterized by muscular weakness, joint pain, and tiredness, occurring in people many years after they have had polio.

Virus isolation in culture is the most sensitive method to diagnose polio. A sample for said culture may be obtained from the throat, stool, or Cerebrospinal Fluid (CSF). Polymerase Chain Reaction (PCR) may be used to differentiate wild strains from vaccine-like strains [ 5 ]. There are no approved antiviral treatments for polio, and the only possible prevention is through vaccination. Immunity is established by the administration of two types of vaccines i.e., Inactivated Polio Vaccine (IPV) and live-attenuated Oral Polio Vaccine (OPV). The Oral Polio Vaccine is more feasible to use as no professional health workers are required to administer it, and it is more cost-efficient. Hence, the OPV is used in mass polio vaccination campaigns in third-world countries including Pakistan. However, OPV has been known to cause Vaccine Associated Paralytic Poliovirus (VAPP), with the type 2 serotype being the most common strain of VAPP. The type 2 strain has now been removed from the Oral Polio Vaccine to limit the incidence of VAPP [ 6 ].

As polio is on the verge of eradication all over the world, there are still some countries that are facing hindrances in eliminating this virus among their peoples. Recently, there has been a hike in the number of cases of Polio Virus in Pakistan. The failure of government policies and planning when it comes to eradicating polio is evident form the fact that eleven cases of polio have been reported in the Northwestern region of Waziristan in 2022 [ 7 ]. Before this recent surge in cases, the last case in Pakistan was reported in 2021 when a child was diagnosed with the case of paralytic poliovirus. Reports suggest that the main causes of the hike in polio cases are false markings, bribery, and refusal of the general public to get their children vaccinated [ 8 ].

In Pakistan, for check and balance, the polio healthcare volunteers mark the thumb or finger of every child they vaccinate to ensure that he/she has received the vaccine dose. However, due to manipulation by certain tribals, unvaccinated children are falsely marked ensuring the healthcare setup in Pakistan that they had achieved their annual locums to vaccinate every single child. The recent rise in polio cases has unveiled this inhumane behavior. Some vaccine fanatics have also falsely reported the vaccination of their unvaccinated children, letting the government believe that their campaign is going smoothly and Pakistan is going towards polio eradication [ 8 ].

Pakistan has faced numerous challenges in its fight against polio. Lack of proper governance, geopolitical instability, insecurity, extremism, hindered access to remote areas, and most importantly the numerous misconceptions of the general public regarding the polio vaccine are just some of the reasons why Pakistan has failed to eradicate polio [ 9 ]. Certain vaccination myths have been quite common in Pakistan. For example, there was a time when there was a certain belief that this vaccination may sterilize the children and that children may lose their fertility. Furthermore, myths like Western countries installing microchips in the form of polio vaccination are still common. There have been numerous incidents in which teams of polio workers have been killed due to people's misconceptions about the polio vaccine. Just recently there has been an attack on a polio vaccination team in northwestern Pakistan in which one health worker and two policemen have been killed [ 10 ]. It is therefore essential that the health services of Pakistan take proper measures not just to ensure the safety of polio workers, but also to spread awareness among the people regarding the importance of vaccination.

Nationwide polio eradication campaigns have been occurring in Pakistan for the last 25 years. Owing to the recent hike in polio cases, Pakistan has also started its anti-polio campaign aiming to vaccinate 12.6 million children in 2022 [ 11 ]. The main purpose of these campaigns is not only to remove the misconceptions regarding the polio vaccine but also to initiate a polio-free environment all over Pakistan. Misconceptions can be dealt with by regular publication of problems that come up if parents refuse to get their child vaccinated. This sort of publication can be done through various social media platforms. Moreover, polio awareness seminars should be conducted frequently all over Pakistan, especially in tribal areas. The data of vaccinated individuals should be regularly checked to ensure that vaccination campaigns meet their annual vaccination goals. Furthermore, myths regarding vaccination should be regularly addressed by the local heads of tribal areas in collaboration with the Government of Pakistan.

Provenance and peer review

Not commissioned, externally peer reviewed.

Not required.

Registration of research studies

• 1. Name of the registry: Not applicable.
• 2. Unique Identifying number or registration ID: Not applicable.
• 3. Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.

Haroon Shabbir, Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.

Sajeel Saeed, Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.

Ethical approval

Not applicable.

Sources of funding

No funding required for the study.

Author contribution

Haroon Shabbir: Study conception, write-up, critical review and approval of the final version. Sajeel Saeed: Study conception, write-up, critical review and approval of the final version. Muhammad Farhan: Write-up, critical review and approval of the final version. Khawar Abbas: Write-up, critical review and approval of the final version. Mohammad Ebad ur Rehman: Write-up and approval of the final version. Fahad Gul: Write-up and approval of the final version. Jawad Basit: Write-up and approval of the final version.

Declaration of competing interest

All authors declared no conflict of interest.

Acknowledgments